- Home
- JHX vs MRNA Comparison
JHX vs MRNA Comparison
Compare JHX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- MRNA
- Stock Information
- Founded
- JHX 1888
- MRNA 2010
- Country
- JHX Ireland
- MRNA United States
- Employees
- JHX N/A
- MRNA N/A
- Industry
- JHX Building Materials
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHX Industrials
- MRNA Health Care
- Exchange
- JHX Nasdaq
- MRNA Nasdaq
- Market Cap
- JHX 14.5B
- MRNA 16.0B
- IPO Year
- JHX N/A
- MRNA 2018
- Fundamental
- Price
- JHX $34.63
- MRNA $35.89
- Analyst Decision
- JHX Buy
- MRNA Hold
- Analyst Count
- JHX 4
- MRNA 20
- Target Price
- JHX $45.00
- MRNA $76.35
- AVG Volume (30 Days)
- JHX 115.9K
- MRNA 10.7M
- Earning Date
- JHX 02-10-2025
- MRNA 02-20-2025
- Dividend Yield
- JHX N/A
- MRNA N/A
- EPS Growth
- JHX N/A
- MRNA N/A
- EPS
- JHX 1.01
- MRNA N/A
- Revenue
- JHX $3,935,900,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- JHX $0.63
- MRNA N/A
- Revenue Next Year
- JHX $8.56
- MRNA N/A
- P/E Ratio
- JHX $33.61
- MRNA N/A
- Revenue Growth
- JHX 5.47
- MRNA N/A
- 52 Week Low
- JHX $29.88
- MRNA $31.94
- 52 Week High
- JHX $43.57
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- JHX 64.42
- MRNA 40.41
- Support Level
- JHX $30.00
- MRNA $33.34
- Resistance Level
- JHX $34.45
- MRNA $35.68
- Average True Range (ATR)
- JHX 0.93
- MRNA 2.53
- MACD
- JHX 0.52
- MRNA -0.60
- Stochastic Oscillator
- JHX 93.35
- MRNA 23.26
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.